Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated

International Journal of Cancer

Volumn 128, Issue 3, 2011, Pages 739-742

  Hann, Hie Won ^a   Bergin, Diane ^a   Coben, Robert ^a   Dimarino, Anthony J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALCOHOL; ANTINEOPLASTIC AGENT; LAMIVUDINE; TENOFOVIR; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CANCER GENE THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOABLATION; DRUG EFFECT; FEMALE; HEPATITIS B; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT RESPONSE; LIVER TUMOR; TUMOR RECURRENCE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 78649867715     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25382     Document Type: Letter

References (10)

1. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
2. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumata H, Omata M, Okita K, Hayashi N, Okanoue T, Lino S, Tanikawa K,; The Inuyama Hepatitis Study Group. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-84.
3. Eun JR, Jang BI, Kim TN, Lee HJ, Lee KS,. The effect of lamivudine on preventing hepatocellular carcinoma in chronic hepatitis B: a retrospective study of 2518 patients. Hepatology 2006; 44: 152A; Poster no. 973.
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Illoeje UH,; REVEAL-HBV Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
5. Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneoshi T, Araki Y, Hashimoto K, Senoch T, Terada R, Nishida T, Kabashi H, Sakaguchi K, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma using an untreated, matched control cohort. Acta Med Okayama 2005; 59: 217-24.
6. Kuzuya T, Katano Y, Kumada T, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H,. Efficacy of antiviral therapy with lamivudine after initial treatment of hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1929-35.
7. Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, Kodai S, Shinkawa H, Sakeguchi H, Tamori A, Habu D, Nishiguchi S,. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007; 37: 94-100.
8. Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanish K, Yamamoto Y, Nakanish M, Kohara TM, Takuya S, Yamamoto K, Horimoto H, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 2009; 44: 991-9.
9. Itai Y, Matsui O,. Blood flow and liver imaging. Radiology 1997; 202: 306-14.
10. Mitchell DG,. MRI for detection and evaluation of hepatocellular carcinoma. In:, Carr BI, ed. Hepatocellular carcinoma: diagnosis and treatment, 2nd edn. New York: Humana Press, 2010. 369-86.